肠道菌群代谢产物与胰岛素抵抗相关衰老疾病的研究进展  

Research progress on metabolites of gut microbiota and insulin resistance-related aging diseases

作　　者：王中英[1] 常丽纳(综述) Xiang Fang(审校) WANG Zhong-ying;CHANG Li-na;Xiang Fang(Teaching and Research Section of Internal Medicine, Heze Medical College, Shandong 274000, China)

机构地区：[1]菏泽医学专科学校内科学教研室,山东274000 [2]菏泽医学专科学校附属医院内分泌科,山东274000 [3]Department of Neurology&The Mitchell Center for Neurodegenerative Diseases,University of Texas Medical Branch,Galveston,Texas 77555,the United States

出　　处：《中国临床新医学》2022年第1期86-90,共5页CHINESE JOURNAL OF NEW CLINICAL MEDICINE

基　　金：山东省中医药科技项目(编号:2020M094)。

摘　　要：2型糖尿病(T2DM)和阿尔茨海默病(AD)都是与年龄相关的衰老性疾病,二者存在多种共同危险因素。肠道微生物通过多种代谢产物参与胰岛素生理机能的调控过程,在胰岛素抵抗(IR)发生发展中发挥重要的作用。该文从IR的角度,对肠道菌群代谢产物与T2DM及AD发病机制的内在联系作一综述。Type 2 diabetes mellitus(T2DM)and Alzheimer′s disease(AD)are both age-related aging diseases,and there are many common risk factors in the two diseases.The gut microbiota participates in the regulation of insulin physiological functions through a variety of metabolites,and plays a vital role in the occurrence and development of insulin resistance(IR).This paper reviews the internal relationship between gut microbiota metabolites and the pathogenesis of T2DM and AD from the perspective of IR.

关 键 词：肠道菌群 胰岛素抵抗 衰老 2型糖尿病 阿尔茨海默病 

分 类 号：R749[医药卫生—神经病学与精神病学]